CN116783181B - 取代的稠合双环类化合物作为parp抑制剂及其应用 - Google Patents
取代的稠合双环类化合物作为parp抑制剂及其应用Info
- Publication number
- CN116783181B CN116783181B CN202280011128.0A CN202280011128A CN116783181B CN 116783181 B CN116783181 B CN 116783181B CN 202280011128 A CN202280011128 A CN 202280011128A CN 116783181 B CN116783181 B CN 116783181B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- optionally substituted
- piperazin
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202610252591.4A CN121800782A (zh) | 2021-04-12 | 2022-04-12 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
| CN202311660486.7A CN117653636B (zh) | 2021-04-12 | 2022-04-12 | 含稠合双环类化合物的抗癌药及该化合物的制药用途 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021103928924 | 2021-04-12 | ||
| CN202110392892 | 2021-04-12 | ||
| CN2021107077396 | 2021-06-24 | ||
| CN202110707739 | 2021-06-24 | ||
| CN202111065912 | 2021-09-10 | ||
| CN2021110659123 | 2021-09-10 | ||
| PCT/CN2022/086311 WO2022218296A1 (en) | 2021-04-12 | 2022-04-12 | Substituted fused bicyclic compounds as parp inhibitors and the use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311660486.7A Division CN117653636B (zh) | 2021-04-12 | 2022-04-12 | 含稠合双环类化合物的抗癌药及该化合物的制药用途 |
| CN202610252591.4A Division CN121800782A (zh) | 2021-04-12 | 2022-04-12 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116783181A CN116783181A (zh) | 2023-09-19 |
| CN116783181B true CN116783181B (zh) | 2026-01-30 |
Family
ID=83640149
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280011128.0A Active CN116783181B (zh) | 2021-04-12 | 2022-04-12 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
| CN202311660486.7A Active CN117653636B (zh) | 2021-04-12 | 2022-04-12 | 含稠合双环类化合物的抗癌药及该化合物的制药用途 |
| CN202610252591.4A Pending CN121800782A (zh) | 2021-04-12 | 2022-04-12 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311660486.7A Active CN117653636B (zh) | 2021-04-12 | 2022-04-12 | 含稠合双环类化合物的抗癌药及该化合物的制药用途 |
| CN202610252591.4A Pending CN121800782A (zh) | 2021-04-12 | 2022-04-12 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240208969A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326713A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024513538A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240009929A (cg-RX-API-DMAC7.html) |
| CN (3) | CN116783181B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216489A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012039A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022218296A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024050370A1 (en) * | 2022-08-30 | 2024-03-07 | 1Cbio, Inc. | Heterocyclic compounds and methods of use thereof |
| WO2024099386A1 (zh) * | 2022-11-10 | 2024-05-16 | 正大天晴药业集团股份有限公司 | 稠合双环化合物 |
| TW202506680A (zh) * | 2023-04-28 | 2025-02-16 | 美商思諾維新醫藥公司 | 作為parp1抑制劑之雜環化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001302515A (ja) * | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ(adp−リボース)ポリメラーゼ阻害剤 |
| JP2002284699A (ja) * | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6908398A (en) * | 1996-10-28 | 1998-05-22 | Versicor Inc | Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones |
| DE602004014640D1 (de) * | 2003-12-19 | 2008-08-07 | Lilly Co Eli | Tricyclische modulatoren von nuklearen steroidhormonrezeptoren |
| JP5100376B2 (ja) * | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキナゾリンジオン誘導体 |
| CN101189238A (zh) * | 2005-02-16 | 2008-05-28 | 先灵公司 | 具有cxcr3拮抗剂活性的哌嗪-哌啶 |
| JP2007137818A (ja) * | 2005-11-17 | 2007-06-07 | Taisho Pharmaceut Co Ltd | 8−ヒドロキシ−2,4(1h,3h)−キナゾリンジオン誘導体 |
| WO2009053373A1 (en) * | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009118384A1 (en) * | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| WO2011006803A1 (en) * | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | 2−アミノ置換8−オキソジヒドロプリン誘導体 |
| US9090568B2 (en) * | 2011-03-14 | 2015-07-28 | Impact Therapeutics, Inc. | Quinazolinediones and their use |
| CN102731416A (zh) * | 2011-04-01 | 2012-10-17 | 南京英派药业有限公司 | 1-(芳基甲基)-喹唑啉-2,4-二酮作为parp抑制剂及其应用 |
| TWI527800B (zh) * | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 作為聚(二磷酸腺苷酸-核醣)聚合酶(parp)之抑制劑之1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮及其應用 |
| RU2014146993A (ru) * | 2012-04-24 | 2016-06-10 | Чугаи Сейяку Кабусики Кайся | Производное хиназолиндиона |
| EP2913330A1 (en) * | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
| CN104892589A (zh) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| WO2018036470A1 (zh) * | 2016-08-22 | 2018-03-01 | 南京明德新药研发股份有限公司 | 作为pde4抑制剂的并环类化合物 |
| WO2018036469A1 (zh) * | 2016-08-22 | 2018-03-01 | 南京明德新药研发股份有限公司 | Pde4抑制剂 |
| WO2018112842A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| TW202039483A (zh) * | 2018-11-22 | 2020-11-01 | 英屬開曼群島商百濟神州有限公司 | 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途 |
-
2022
- 2022-04-12 CN CN202280011128.0A patent/CN116783181B/zh active Active
- 2022-04-12 CN CN202311660486.7A patent/CN117653636B/zh active Active
- 2022-04-12 CN CN202610252591.4A patent/CN121800782A/zh active Pending
- 2022-04-12 MX MX2023012039A patent/MX2023012039A/es unknown
- 2022-04-12 KR KR1020237037924A patent/KR20240009929A/ko active Pending
- 2022-04-12 CA CA3216489A patent/CA3216489A1/en active Pending
- 2022-04-12 WO PCT/CN2022/086311 patent/WO2022218296A1/en not_active Ceased
- 2022-04-12 US US18/554,980 patent/US20240208969A1/en active Pending
- 2022-04-12 EP EP22787519.2A patent/EP4326713A4/en active Pending
- 2022-04-12 JP JP2024505487A patent/JP2024513538A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001302515A (ja) * | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ(adp−リボース)ポリメラーゼ阻害剤 |
| JP2002284699A (ja) * | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024513538A (ja) | 2024-03-25 |
| MX2023012039A (es) | 2024-03-05 |
| CN121800782A (zh) | 2026-04-07 |
| US20240208969A1 (en) | 2024-06-27 |
| KR20240009929A (ko) | 2024-01-23 |
| EP4326713A4 (en) | 2025-03-19 |
| EP4326713A1 (en) | 2024-02-28 |
| CN116783181A (zh) | 2023-09-19 |
| CN117653636A (zh) | 2024-03-08 |
| CA3216489A1 (en) | 2022-10-20 |
| WO2022218296A1 (en) | 2022-10-20 |
| CN117653636B (zh) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7240784B2 (ja) | 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物 | |
| CN117980307A (zh) | 取代的三环类化合物作为parp抑制剂及其应用 | |
| KR102388312B1 (ko) | 아미노피리미딘 화합물, 이의 제조방법 및 용도 | |
| CN118215664B (zh) | 取代的三唑并杂芳基化合物作为usp1抑制剂及其应用 | |
| CN117653636B (zh) | 含稠合双环类化合物的抗癌药及该化合物的制药用途 | |
| CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| CN119013279A (zh) | 作为parp抑制剂的取代的三环类化合物及其应用 | |
| WO2017092635A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
| CN117412973A (zh) | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 | |
| CN112457306A (zh) | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 | |
| CN104066723A (zh) | 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用 | |
| CN116670134A (zh) | 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用 | |
| JP2022548055A (ja) | 置換イミダゾキノキサリン化合物およびその応用 | |
| CN120826404A (zh) | 取代的含氮三环类化合物作为parp抑制剂及其应用 | |
| CN121627671A (zh) | 靶向Polθ的乙烯基磺酰基取代的化合物及其应用 | |
| HK40104162A (en) | Substituted tricyclic compounds as parp inhibitors and use thereof | |
| HK40115331A (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
| CN112480120A (zh) | 取代的咪唑并喹喔啉化合物及其应用 | |
| CN104557955A (zh) | 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |